Perspective Therapeutics (CATX) Competitors

Perspective Therapeutics (NYSE:CATX) and InMode (NASDAQ:INMD) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.

Does the media prefer CATX or INMD?

In the previous week, Perspective Therapeutics had 5 more articles in the media than InMode. MarketBeat recorded 10 mentions for Perspective Therapeutics and 5 mentions for InMode. InMode's average media sentiment score of 1.27 beat Perspective Therapeutics' score of 0.10 indicating that InMode is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Perspective Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
InMode	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility and risk, CATX or INMD?

Perspective Therapeutics has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500. Comparatively, InMode has a beta of 2, meaning that its share price is 100% more volatile than the S&P 500.

Do analysts recommend CATX or INMD?

Perspective Therapeutics currently has a consensus target price of $12.56, indicating a potential upside of 262.88%. InMode has a consensus target price of $18.04, indicating a potential upside of 20.44%. Given Perspective Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Perspective Therapeutics is more favorable than InMode.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Perspective Therapeutics	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.18
InMode	0 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.13

Which has higher valuation and earnings, CATX or INMD?

InMode has higher revenue and earnings than Perspective Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Perspective Therapeutics	N/A	N/A	-$46.51M	N/A	N/A
InMode	$401.56M	2.36	$181.27M	$2.47	6.06

Do insiders and institutionals hold more shares of CATX or INMD?

54.7% of Perspective Therapeutics shares are held by institutional investors. Comparatively, 68.0% of InMode shares are held by institutional investors. 3.7% of Perspective Therapeutics shares are held by company insiders. Comparatively, 6.9% of InMode shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Is CATX or INMD more profitable?

InMode has a net margin of 44.50% compared to Perspective Therapeutics' net margin of -4,096.66%. InMode's return on equity of 18.38% beat Perspective Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Perspective Therapeutics	-4,096.66%	-27.40%	-23.16%
InMode	44.50%	18.38%	16.35%

Summary

InMode beats Perspective Therapeutics on 9 of the 14 factors compared between the two stocks.